<DOC>
	<DOCNO>NCT02251314</DOCNO>
	<brief_summary>Despite recent advance cancer treatment , little impact make cure opposed control cancer last several decade . Part problem investigator incomplete understanding tumour behave evolve response treatment . In trial , investigator hope good understand evolution BRAF melanoma response drug patient may receive vemurafenib dabrafenib . Importantly , investigator want understand tumour evolve resistance drug whether predict blood test , particular circulate tumour DNA .</brief_summary>
	<brief_title>Use Exome Sequence Analysis Circulating Tumour Assessing Tumour Heterogeneity BRAF Mutant Melanoma</brief_title>
	<detailed_description>Study population : BRAF mutant melanoma patient Pre-mortem blood take patient three occasion one thirty day apart , first blood draw take place patient 's first clinic visit . Six 7 ml EDTA one 6 ml SST vacutainers blood ( total approx . 50 ml blood ) take patient . When death expect within next 48-72 hour , Medical Oncologist/ Radiation Oncologist/ Hematologist OR delegate revisit RAP process patient and/or family/substitute decision maker ensure still agreement . The patient family also provide additional consent form participation include blood sampling .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>UHN adult patient BRAF mutant melanoma Non BRAF mutant melanoma patient Pediatric patient NonUHN patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>BRAF mutant melanoma</keyword>
	<keyword>circulation tumour DNA</keyword>
	<keyword>tumour heterogeneity</keyword>
	<keyword>liquid biopsy</keyword>
</DOC>